Robust T cell Responses Reported Across Diverse HLA backgrounds in Ph 2 AMPLIFY-7P Trial of ELI-002
Robert Connelly, Chief Executive Officer of Elicio, commented, “We are extremely pleased to see that mKRAS-specific T cell responses are induced among patients with a diverse HLA background, suggesting that ELI-002 7P may be applicable to a broad range of PDAC patients potentially addressing a key unmet need and expanding the potential market opportunity. Our observations build on past data to show that the majority of patients express mKRAS-presenting HLAs, likely enabling T cell recognition in most patients. These encouraging findings highlight the potential for ELI-002 7P to benefit a broader spectrum of PDAC patients, which may extend the reach of immunotherapy to more individuals and address a critical unmet need.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us